evipedia.ai
← Back

Mung Bean Extract for Health & Longevity

Evidence Review created on 11/05/2026 using AI4L / Opus 5.5

Also known as: Vigna radiata Extract, Phaseolus aureus Extract, Green Gram Extract, Moong Bean Extract, Mungbean Extract, Mung Bean Seed Coat Extract, Mung Bean Hull Extract

Motivation

Mung bean extract is a concentrated preparation of the mung bean (Vigna radiata), a small green legume eaten across Asia. Products sold under this name come in two main kinds: extracts of the seed coat, rich in plant pigments, and protein powders or protein fragments drawn from the bean itself. Interest rests on the idea that these concentrates may deliver, in a capsule or drink, plant compounds that laboratory work connects to blood sugar handling, inflammation, and blood vessel health.

Mung beans have a long history in Chinese and Indian traditional medicine, usually as soups and porridges. Over the last two decades, laboratory groups have tested seed-coat extracts in mice, worms, and cell cultures, and a food company has sponsored human studies of its branded mung bean protein. Apart from one early trial of a mung bean pigment product in cancer patients, human research on these products began only in the last decade.

This review examines what the human, animal, and laboratory evidence shows for mung bean extracts, which forms have been tested, what risks and drug interactions are reported, and how the products are dosed, sourced, and monitored by adults pursuing demanding health and longevity protocols.

Benefits - Risks - Protocol - Conclusion

This section lists overview-level reading on mung bean extract from a priority expert publication and from the academic literature.

No dedicated content on mung bean extract was found from Rhonda Patrick, Peter Attia, Andrew Huberman, or Lifespan.io: web searches and each site’s own search returned nothing relevant. Chris Kresser’s site mentions whole mung beans only in passing, as an easily digested legume in an Ayurvedic elimination diet, and does not discuss extracts.

Grokipedia

  • Mung bean

    There is no page on the extract itself; this article covers the plant’s taxonomy, cultivation, nutritional composition, and sprout and culinary uses, which is background on the source rather than extract evidence.

Examine

No Examine article on mung bean or mung bean extract exists; Examine also has no entry for vitexin, the main seed-coat flavonoid.

ConsumerLab

No ConsumerLab article on mung bean extract exists.

Systematic Reviews

This section lists the one systematic review on PubMed that covers mung bean products, which addresses safety rather than benefit.

No systematic review or meta-analysis of any claimed benefit of mung bean extract or mung bean protein was found, so the benefit side of the trade-off is unrepresented.

Mechanism of Action

Mung bean extracts act through two ingredient families, depending on the product:

  • Seed-coat flavonoids: Vitexin and isovitexin (sugar-bound plant pigments) dominate the hull. In roundworms and rat cells, coat extract activated AMPK (AMP-activated protein kinase, the cell’s energy sensor) and autophagy (cellular self-cleaning) (Chen 2026); in macrophages (immune cells that engulf debris) it promoted autophagic breakdown of HMGB1 (Zhu 2012).
  • Proteins and peptides: The protein isolate cut liver fat and fat-synthesis gene activity in mice (Watanabe 2017, co-authored by staff of the isolate’s manufacturer, Fuji Oil). Hydrolyzed protein blocked NF-κB (nuclear factor kappa B, a master switch for inflammatory genes) in macrophages (Diao 2019), and enzyme hydrolysis of the protein releases peptides that inhibit ACE (angiotensin-converting enzyme, which raises blood pressure) in test tubes (Li 2006).

Pharmacology: In rats, oral seed-extract flavonoids peak at about 1.5 hours, distribute widely, and largely clear within 4 hours without accumulating (Bai 2017); intravenous isovitexin has a half-life near 1 hour and concentrates in kidney, intestine, and liver (Li 2015). Vitexin loses about 94% to intestinal first-pass metabolism (breakdown in the gut wall before reaching the bloodstream), and verapamil, an inhibitor of P-gp (P-glycoprotein, a drug-efflux pump) and CYP3A (a major drug-metabolizing enzyme), barely changed its exposure (Xue 2014).

Competing view: Such low systemic exposure suggests effects, if any, occur mainly in the gut. Vitexin also inhibits thyroid peroxidase (the enzyme that makes thyroid hormone) (Gaitan 1995), a potential harm.

Historical Context & Evolution

  • Original use: Mung beans became a staple pulse across Asia after domestication in South Asia. Chinese medicine has used mung bean preparations since the 1050s against inflammatory conditions (Zhu 2012), and Ayurveda treats mung beans as the most digestible legume, the base of the dish khichuri (Revolution Health Radio episode). These uses involved whole cooked beans, not extracts.
  • Path to health optimization: Chemists characterized the seed-coat flavonoids, peptides, and sprout metabolites, as summarized in a narrative review (Tang 2014). Seed-coat and sprout extracts lowered blood glucose in diabetic mice (Yao 2008), and a coat extract improved survival in septic mice in a study its authors framed as testing folklore (Zhu 2012). Fuji Oil ran human trials of its protein isolate in 2013–2016 (Kohno 2018), and in 2017 the U.S. Food and Drug Administration (FDA) closed a GRAS (generally recognized as safe) notice from Hampton Creek for another isolate with no questions (FDA GRN 684). Longevity interest grew after a coat extract extended roundworm lifespan (Tao 2021).
  • Evolution of opinion: Early claims rested on test-tube antioxidant assays. Later work moved to specific pathways and asked whether poorly absorbed flavonoids reach tissues at all. Human data exist mainly for protein forms; the only trial of a vitexin-based extract tested radiotherapy tolerance in cancer patients (Hien 2002), so the traditional and laboratory claims for seed-coat extracts are neither confirmed nor refuted in healthy people.

Expected Benefits

High 🟩 🟩 🟩

No benefit reaches High: the human data are three small trials of mung bean protein products and one small trial of a vitexin-based extract, each from a single research group and none replicated; other seed-coat data are animal, roundworm, and cell studies.

Medium 🟩 🟩

Blood-Count Protection During Radiotherapy ⭕️ Not Central to Health & Longevity

Vitexina, a Vietnamese Vigna radiata product with the flavonoid vitexin as its main component, was compared with placebo in breast cancer patients during 6 weeks of cobalt-60 radiotherapy (Hien 2002). Peripheral blood cell counts and lymphocyte (a type of white blood cell) function were better preserved, and weight loss was less common. This bears on tolerance of cancer radiotherapy, not on longevity in healthy adults. The trial is single-center, its size is not given in the abstract, and it is unreplicated.

Magnitude: No relevant weight loss occurred in 70% of the Vitexina group, while 73% of the placebo group lost 1–2 kg over 6 weeks (not compared between groups); the abstract reports the blood-cell protection as significant but gives no figures.

Endothelial Function

In adults aged 45–60, 10–15 g/day of mung bean protein for 6 weeks increased flow-mediated dilation (FMD, artery widening after cuff release, a marker of vessel-lining health) versus a placebo drink of the same ingredients without the mung bean protein (Muchimapura 2024). Only 27 participants completed this single-center, three-arm trial from one Khon Kaen University group, and it is unreplicated. FMD predicts cardiovascular events but is not an established treatment target.

Magnitude: The percentage change in FMD rose significantly more in both mung bean groups than with placebo; the paper presents the values only in figures and reports no numeric outcome figure in its text. TNF-α (tumor necrosis factor alpha) and IL-6 (interleukin 6), two inflammatory signaling proteins, and NF-κB also fell versus placebo.

Low 🟩

Insulin Sensitivity and Triglycerides ⚠️ Conflicted

Mung bean protein isolate lowered fasting insulin and insulin resistance within-group in trials by staff of its maker, Fuji Oil (Kohno 2018). Fasting glucose was unchanged; week-8 differences versus casein (milk protein) were nonsignificant. Seed-coat extract lowered glucose in diabetic mice (Yao 2008). Net: unconfirmed against control.

Magnitude: In 44 overweight adults given 3 g/day for 8 weeks, fasting insulin went from 14.9 to 10.8 μU/mL with the isolate versus 12.2 to 13.7 μU/mL with casein, and HOMA-IR (homeostatic model assessment of insulin resistance, an index computed from fasting glucose and insulin) from 3.8 to 2.9 versus 2.8 to 3.3; triglycerides went from 153 to 142 versus 136 to 146 mg/dL (between-group trend, P < 0.1, where P is the probability that a difference this large arises by chance), and fasting glucose from 102 to 99 versus 97 to 98 mg/dL. The abstract reports significant decreases in insulin, HOMA-IR, and triglycerides, but the full-text table marks insulin and HOMA-IR as within-group changes only and triglycerides as a between-group trend, with no significant difference between groups at week 8.

Muscle Strength on Plant-Based Diets ⚠️ Conflicted

In underactive vegetarians, 18 g/day of mung bean protein for 8 weeks, without exercise training, produced a small relative strength gain (Bartholomae 2019). End-of-trial strength and lean mass did not differ between groups, and only 25 participants completed. Net: a borderline signal from one small trial.

Magnitude: The average percent change in grip, knee flexor, and knee extensor strength (mean ± standard deviation, the typical spread of individual results around the average) was +2.9 ± 7.2% with mung bean protein (n = 11) versus −2.6 ± 7.3% with control (n = 14), P = 0.05; lean body mass did not differ between groups.

Liver Enzymes ⚠️ Conflicted

In the manufacturer-authored trial, ALT (alanine aminotransferase, a liver enzyme that rises with liver fat or injury) fell within the isolate group but not versus casein (Kohno 2018). In mice, the isolate prevented liver fat and fibrosis (scarring) (Watanabe 2017). Net: unconfirmed against control.

Magnitude: ALT went from 35.3 to 30.6 IU/L with the isolate versus 31.0 to 31.6 IU/L with casein over 8 weeks, with no significant between-group difference at week 8; the abstract describes improved liver enzymes, but the full-text table shows a within-group change only.

Speculative 🟨

Inflammation and Sepsis Resilience

Seed-coat extract reduced HMGB1 release from cultured macrophages, and oral dosing raised septic-mouse survival, possibly via autophagic HMGB1 breakdown (Zhu 2012). Hydrolyzed protein blocked NF-κB in cells (Diao 2019). Basis: animal and cell data only.

Lifespan and Stress Resistance

A vitexin- and isovitexin-rich coat extract extended roundworm (Caenorhabditis elegans) lifespan and heat and oxidative stress resistance, partly through calorie-restriction-like pathways (Tao 2021). Basis: invertebrate data only; no mammalian lifespan study exists.

Neuroprotection

Coat extract reduced toxic protein clumping (amyloid-β, tau, α-synuclein) in worm models of Alzheimer’s and Parkinson’s disease and in rat cells through AMPK-dependent autophagy (Chen 2026). Basis: worm and cell data only.

Gut Microbiota Support

In human stool fermented in the laboratory, seed-coat polyphenol extract raised Bifidobacterium, Lactobacillus, and Faecalibacterium prausnitzii counts and lowered Escherichia-Shigella (Charoensiddhi 2022). Basis: laboratory fermentation only; no human feeding study.

Blood Pressure Regulation

Peptides from enzyme-digested mung bean protein inhibit ACE in test tubes (Li 2006), the target of ACE-inhibitor drugs. No controlled human study reports a blood-pressure effect of an extract. Basis: laboratory data only.

Heat-Stress Protection

In heat-stressed intestinal cells, polyphenol extract, vitexin, and orientin lowered expression of heat-shock protein 70 (a cell stress-response protein), consistent with traditional summer-heat use (Feng 2022). Basis: cell data only; no animal or human outcome.

Benefit-Modifying Factors

  • Genetic polymorphisms: No study has tested whether gene variants change response to mung bean extracts; differences in the gut bacteria that process plant flavonoids may matter more for seed-coat extracts, but this is untested.
  • Baseline biomarkers: In the GLUCODIA trial, insulin and triglyceride changes were larger in participants with HOMA-IR ≥ 1.7, the authors’ cut-off for low insulin sensitivity (Kohno 2018); people with normal fasting insulin have less room to improve.
  • Sex: The three protein trials (Kohno 2018; Muchimapura 2024; Bartholomae 2019) enrolled men and women but reported no sex-specific results, and the vitexin-extract trial (Hien 2002) enrolled only women; no sex difference in benefit is known.
  • Pre-existing conditions: Signals appeared in overweight adults with mild insulin resistance and raised triglycerides (Kohno 2018) and in underactive vegetarians (Bartholomae 2019); people already well nourished and metabolically healthy were not studied for these outcomes.
  • Age: The endothelial trial enrolled 45–60-year-olds (Muchimapura 2024) and no trial enrolled adults over 65, whose higher protein needs could, as an untested inference, make protein forms more relevant.

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: harm data come from small trials with only a few adverse events per arm, from allergy case series, and from animal studies.

Medium 🟥 🟥

No risk reaches Medium: the allergy evidence consists of case series and sensitization studies without comparison groups, and trial adverse-event data are too sparse to compare between arms.

Low 🟥

Allergic Reactions in Birch-Pollen- and Legume-Sensitized People

Mung bean’s Vig r 1, a pollen-related allergen, cross-reacts with birch pollen; case series from Zurich (Mittag 2005) and Vienna (Guhsl 2014) describe reactions to sprouts, not extracts. EFSA (European Food Safety Authority) states the protein isolate may trigger reactions in soy-, peanut-, lupin-, or birch-allergic people (EFSA 2021).

Magnitude: In a case series of 10 birch-allergic patients with reactions to mung bean sprouts, 80% had IgE (immunoglobulin E, the antibody behind allergic reactions) against Vig r 1 (no control group); the rate of reactions among extract users has not been measured.

Gastrointestinal Discomfort ⚠️ Conflicted

In the manufacturer-authored GLUCODIA trials, mild gastrointestinal events such as diarrhea, bloating, and dyspepsia (indigestion) occurred at a similar rate with casein, all judged unrelated or unlikely related (Kohno 2018). Whole legumes cause gas through fermentable sugars; how much extracts retain is unmeasured. Net: plausible but not shown above control.

Magnitude: In the 8-week main trial, 3 mild gastrointestinal events (dyspepsia in 2, infrequent bowel movements in 1) occurred with the isolate versus 2 with casein (nausea, upper abdominal pain), 22 participants per arm; no statistical comparison was reported.

Lowered Tacrolimus and Cyclosporine Blood Levels

A case letter reported lower trough levels (the lowest blood level, just before the next dose) of tacrolimus, a transplant anti-rejection drug, after mung bean soup (Hu 2024). Seed-coat extract cut cyclosporine exposure by 47% in rats (Li 2014). Low levels raise rejection risk; human reports involved soup, not extract.

Magnitude: For tacrolimus, direction only: trough levels fell in a single reported patient (no control group), and the letter has no abstract or retrievable figures. For cyclosporine, a Chinese report cited in the rat study (Li 2014) describes troughs falling from 390 to 287 ng/mL after mung bean food in renal transplant recipients, six with graft rejection (no control group).

Speculative 🟨

Thyroid Hormone Suppression

Vitexin, a main seed-coat flavonoid, inhibits thyroid peroxidase and impaired thyroid hormone formation in rats at high doses (Gaitan 1995); vitexin-rich millet diets are goitrogenic (cause thyroid enlargement). Basis: animal and laboratory data only.

Reduced Iron Absorption

Seed-coat polyphenols, like tea polyphenols, can bind non-heme iron (iron from plants and supplements) in the gut, so concentrated extracts could lower absorption. Basis: mechanistic inference only; no study has measured it with extracts.

Risk-Modifying Factors

  • Genetic polymorphisms: No gene variant is known to change the risks of mung bean extract; an inherited tendency to allergy (atopy) raises the chance of birch-pollen and legume sensitization, the precondition for Vig r 1 cross-reactions (Mittag 2005).
  • Baseline biomarkers: A high-normal TSH (thyroid-stimulating hormone) or low iodine intake would make vitexin’s antithyroid action more relevant, and low ferritin (stored iron) makes reduced iron absorption more relevant; both are inferences from mechanism.
  • Sex: No sex-specific harm data exist; women of reproductive age more often have low iron stores, which raises the relevance of iron binding, and no safety data cover pregnancy or breastfeeding.
  • Pre-existing conditions: Birch-pollen, soy, peanut, or lupin allergy (EFSA 2021); organ transplant on tacrolimus or cyclosporine (Hu 2024; Li 2014); hypothyroidism; iron deficiency; diabetes treated with glucose-lowering drugs; and irritable bowel syndrome, given fermentable legume sugars.
  • Age: Older adults more often take several drugs, including narrow-margin ones such as tacrolimus or glucose-lowering agents, and have lower stomach acid that can impair iron absorption, so interaction and iron concerns weigh more heavily.

Key Interactions & Contraindications

Documented interactions:

  • Tacrolimus: A case letter reported lower tacrolimus trough levels after mung bean soup (Hu 2024); the consequence is under-immunosuppression and transplant rejection risk. Mitigation: trough-level check within 1–2 weeks of starting or stopping any mung bean product.
  • Cyclosporine: Seed-coat extract cut cyclosporine exposure by 47% in rats (Li 2014), and a Chinese report cited there describes falling troughs and graft rejection after mung bean soup; the consequence is transplant rejection risk. Mitigation: trough-level check within 1–2 weeks of starting or stopping.

Theoretical interactions (inferred from mechanism, not studied in humans):

  • Glucose-lowering drugs (metformin, glimepiride, insulin): Inferred from insulin lowering in the protein-isolate trial (Kohno 2018) and glucose lowering in seed-coat mouse data (Yao 2008); the consequence is hypoglycemia (abnormally low blood sugar). Mitigation: home glucose checks during the first 2–4 weeks.
  • ACE inhibitors and other antihypertensives (lisinopril, enalapril, amlodipine): Inferred from ACE-inhibiting mung bean peptides in test tubes (Li 2006); the consequence is additive blood pressure lowering with dizziness. Mitigation: home blood pressure checks after starting.
  • Thyroid drugs (levothyroxine, methimazole): Inferred from vitexin’s thyroid peroxidase inhibition in rats (Gaitan 1995); the consequence is altered thyroid control. Mitigation: TSH check 6–8 weeks after starting a seed-coat extract.
  • Other narrow-margin CYP3A substrates (sirolimus, everolimus): Inferred from vitexin’s inhibition of CYP3A, and induction or inhibition of CYP2C (another drug-metabolizing enzyme family), in rats (Wang 2015); the consequence is altered drug levels. Mitigation: drug-level monitoring after starting or stopping.
  • Warfarin, with sprout-based products: Inferred from the vitamin K content of sprouted beans, which opposes warfarin; the consequence is reduced anticoagulation. Mitigation: INR (international normalized ratio, a clotting-time test) check after starting.
  • Over-the-counter iron and zinc preparations (ferrous sulfate, zinc gluconate): Inferred from polyphenol and phytate (a mineral-binding plant compound) binding of minerals in the gut; the consequence is lower mineral absorption. Mitigation: doses taken at least 2 hours apart.
  • Glucose-lowering supplements (berberine, chromium, cinnamon, alpha-lipoic acid): Inferred from additive effects on insulin and glucose; the consequence is low blood sugar, mainly with concurrent diabetes drugs. Mitigation: introducing one product at a time with glucose checks.
  • Blood-pressure-lowering supplements (garlic extract, beetroot nitrate, fish oil): Inferred from additive blood pressure lowering with ACE-inhibiting peptides; the consequence is lightheadedness. Mitigation: home blood pressure checks.
  • Fasting and very-low-carbohydrate diets: Inferred from additive lowering of insulin and glucose; the consequence is hypoglycemia in people on glucose-lowering drugs. Mitigation: glucose monitoring during combined use.

Populations who should avoid Mung Bean Extract:

  • People with confirmed mung bean allergy or birch-pollen-related food allergy with Vig r 1 sensitization (Mittag 2005).
  • People allergic to soy, peanut, or lupin, unless testing excludes cross-reactivity, per the EFSA allergen statement (EFSA 2021).
  • Organ transplant recipients on tacrolimus or cyclosporine without trough-level monitoring (Hu 2024; Li 2014).
  • People with untreated hypothyroidism or iodine deficiency taking seed-coat extracts: inferred from vitexin’s antithyroid action in rats (Gaitan 1995); no human data.

Risk Mitigation Strategies

Doses, timings, and thresholds below follow common practice unless cited.

  • Allergy screening first: People with birch-pollen, soy, peanut, or lupin allergy typically undergo specific IgE or skin-prick testing to mung bean before use, mitigating allergic reactions (EFSA 2021).
  • Low starting dose: Starting at half the target dose (for example, 1.5 g/day of protein isolate, the lowest dose tested by Kohno 2018) for one week limits gastrointestinal discomfort.
  • Transplant-drug trough check: Transplant recipients on tacrolimus or cyclosporine who use any mung bean product have a trough level drawn 1–2 weeks after starting or stopping, preventing unrecognized under-immunosuppression (Hu 2024; Li 2014).
  • Glucose monitoring: People on glucose-lowering drugs check fasting and pre-meal glucose daily for 2–4 weeks after starting, which prevents unrecognized hypoglycemia.
  • Thyroid check: TSH at baseline and 8 weeks after starting a seed-coat extract detects antithyroid effects suggested by rat data (Gaitan 1995).
  • Separation from iron: Taking seed-coat extracts at least 2 hours apart from iron supplements or iron-rich meals reduces the risk of lower iron absorption.

Therapeutic Protocol

Doses below are cited to their source; other parameters without a citation (timing, titration, cycling, reassessment points) reflect common practice.

  • Protein isolate for metabolic goals: 3 g/day of GLUCODIA mung bean protein isolate, split before breakfast and dinner, for 8 weeks; 1.5 and 6 g/day were tested for 4 weeks (Kohno 2018, manufacturer-run).
  • Protein drink for vascular goals: 10 or 15 g/day of mung bean protein in a drink taken before meals for 6 weeks (Muchimapura 2024).
  • Protein supplement for strength: 18 g/day of mung bean protein for 8 weeks in underactive vegetarians (Bartholomae 2019).
  • Seed-coat (vitexin and isovitexin) extracts: No dose has been tested in healthy adults, and the radiotherapy trial’s abstract gives none (Hien 2002); one marketed label gives 240 mg coat extract daily without food (Life Extension product page).
  • Whole-food alternative: Traditional Chinese practice uses boiled whole mung beans or soup rather than extracts (Tang 2014); this delivers the coat, protein, and fiber together at food doses.
  • Who popularized each approach: Fuji Oil developed the protein isolate; Haichao Wang’s Feinstein Institutes laboratory drove seed-coat inflammation interest (Zhu 2012); Life Extension Magazine, from a supplement retailer, promoted the extract (Life Extension Magazine article).
  • Time of day: GLUCODIA dosing was before breakfast and dinner (Kohno 2018), protein drinks before meals (Muchimapura 2024), and the strength trial’s food in the morning (Bartholomae 2019); no trial compared times of day.
  • Half-life: Seed-coat flavonoids peak about 1.5 hours after an oral dose and largely clear within 4 hours in rats (Bai 2017); proteins are digested into peptides and amino acids within hours. No human pharmacokinetic (absorption and clearance) data exist.
  • Single versus split dosing: The short flavonoid half-life favors split doses with meals, and the GLUCODIA trials divided the daily dose into two portions (Kohno 2018).
  • Genetic polymorphisms: No pharmacogenetic data exist, and no gene variant is known to alter dose choice for any mung bean extract.
  • Sex: The trials pooled men and women and reported no sex-specific dose findings; the same doses were used for both sexes.
  • Age: Tested ages ranged from 18 to 65; older adults, who need more protein to maintain muscle, may favor protein forms, but no dose data exist above age 65.
  • Baseline biomarkers: Insulin effects were concentrated in participants with HOMA-IR ≥ 1.7 (Kohno 2018), so metabolic use is most plausible when fasting insulin is elevated.
  • Pre-existing conditions: People on glucose-lowering drugs, thyroid drugs, tacrolimus, or cyclosporine face the monitoring needs listed under Key Interactions; people with birch-pollen or legume allergies are typically tested before a first dose.

Discontinuation & Cycling

  • Duration: Human trials lasted 6–8 weeks; whether use is meant to be short-term or lifelong is undefined, and no safety or efficacy data exist beyond 8 weeks.
  • Withdrawal effects: None have been reported, and no mechanism for dependence or rebound is known.
  • Tapering: No taper is needed pharmacologically; the exception is tacrolimus or cyclosporine users, whose trough level may rise after stopping, inferred from the reported decreases (Hu 2024; Li 2014), so a recheck follows discontinuation.
  • Cycling: No study has tested cycling, and there is no evidence that breaks maintain efficacy or that tolerance develops.
  • Reassessment point: Comparing fasting insulin, triglycerides, or other target markers with baseline after 8–12 weeks, the trial window, shows whether continuing has a measurable rationale.

Sourcing and Quality

  • Extract types: Seed-coat polyphenol extracts (vitexin and isovitexin), protein isolates or peptides, and sprout extracts are different products (Hou 2019); human data exist mainly for protein forms.
  • Standardization: For seed-coat extracts, a stated and HPLC-verified (high-performance liquid chromatography, a lab assay) vitexin and isovitexin content per dose is the main quality marker; unstandardized “mung bean extract” gives no assurance of either compound.
  • Protein isolate regulatory status: Hampton Creek’s mung bean protein isolate has an FDA GRAS notice closed with no questions (FDA GRN 684), and EFSA judged mung bean protein safe at proposed uses (EFSA 2021).
  • Third-party testing: Certification by USP (United States Pharmacopeia), NSF, or Informed Choice verifies identity and contaminants; few mung bean extracts carry such seals, so a batch certificate of analysis is the practical substitute.
  • Heavy metals: Mung bean plants accumulate arsenic, cadmium, and lead when irrigated with contaminated water (Anwar 2021), so batch testing for these metals matters, especially for products sourced from regions with known contamination.
  • Allergen processing: Protein extraction removes much of the seed albumin allergen but concentrates cupin allergens (storage-protein allergens) (Chin 2024), so isolates are not hypoallergenic.
  • Brands with data: GLUCODIA (Fuji Oil) protein isolate (Kohno 2018) and the JUST Egg mung bean protein patty (Bartholomae 2019) have published human trials; among seed-coat products, only the Vietnamese vitexin-based Vitexina has one, in cancer radiotherapy (Hien 2002).
  • Seed-coat extract products: Life Extension’s Cytokine Suppress, from the publisher of the Life Extension Magazine article, combines 240 mg coat extract (24 mg vitexin, 24 mg isovitexin) with EGCG (epigallocatechin gallate, a green tea polyphenol) (Life Extension product page).

Practical Considerations

  • Time to effect: Trial changes in insulin, FMD, and strength were measured at 6–8 weeks (Kohno 2018; Muchimapura 2024; Bartholomae 2019); no data describe earlier or longer timelines.
  • Pitfall – conflating forms: Roundworm lifespan and mouse sepsis data apply to seed-coat extracts, while the metabolic, vascular, and strength trials used protein products; evidence for one form does not transfer to the other.
  • Pitfall – assuming food-level safety: The long dietary history of mung beans does not establish the safety of concentrated vitexin, for which thyroid and iron concerns arise from animal and mechanistic data (Gaitan 1995).
  • Regulatory status (United States): Mung bean extracts are sold as dietary supplements, which the FDA does not approve before sale (FDA dietary supplements page); Hampton Creek’s mung bean protein isolate is a GRAS food ingredient for its notified uses (FDA GRN 684).
  • Regulatory status (European Union): EFSA concluded that mung bean protein is safe as a novel food at the proposed conditions of use (EFSA 2021).
  • Cost and access: Mung bean protein and seed-coat extracts are inexpensive and widely sold online; cost is not a barrier.

Interaction with Foundational Habits

  • Sleep: Direction: none known. No study has measured sleep outcomes, and no stimulant constituent is known; the GLUCODIA trials dosed before breakfast and dinner (Kohno 2018), and no trial dosed at bedtime.
  • Nutrition: Direction: indirect. Protein forms add 3–18 g/day of protein toward daily targets; seed-coat polyphenols may reduce iron uptake from plant foods, and a registered trial tested vitamin C-rich guava to improve iron absorption from mung bean meals (NCT01191463).
  • Exercise: Direction: potentiating, inferred. Mung bean protein improved strength slightly even without training (Bartholomae 2019); combination with resistance training is untested, and taking protein after training follows common practice.
  • Stress management: Direction: none established in humans. Fermented and germinated mung bean extracts reversed restraint-stress markers, including adrenal weight and brain antioxidant enzymes, in mice (Yeap 2014); no human cortisol data exist.

Monitoring Protocol & Defining Success

Baseline testing before starting sets the reference point: fasting glucose, fasting insulin, triglycerides, and ALT for metabolic goals; TSH and ferritin as safety checks when seed-coat extracts are used; specific IgE testing for people with birch-pollen, soy, peanut, or lupin allergy; and a tacrolimus or cyclosporine trough level for transplant recipients.

Ongoing monitoring follows the trial windows: metabolic markers at 8 weeks, then every 6–12 months while use continues; TSH at 8 weeks, then annually; ferritin at 8–12 weeks, then annually, with seed-coat extracts; and tacrolimus or cyclosporine trough levels 1–2 weeks after starting or stopping. Fasting samples are drawn in the morning after 10–12 hours without food, as in the GLUCODIA trials (Kohno 2018). Success is defined as a sustained change from the individual’s own baseline in the targeted marker without safety-marker deterioration.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Fasting insulin About 2.6–24.9 μU/mL (standard reference range; varies by laboratory) Expected to change (fell within-group with protein isolate) Fasting 10–12 h; morning draw; pair with fasting glucose; track change from own baseline (Kohno 2018)
HOMA-IR No established target; track change from own baseline Expected to change Computed as insulin (μU/mL) × glucose (mg/dL) ÷ 405; 1.7 was the trial cut-off for low insulin sensitivity (Kohno 2018)
Fasting glucose 70–99 mg/dL (standard reference range) Safety check for hypoglycemia with glucose-lowering drugs Did not change with the isolate in the main trial (Kohno 2018); pair with insulin
Triglycerides Below 150 mg/dL (standard reference range) Expected to change Fasting sample; trend-level fall in the main trial (Kohno 2018)
ALT About 7–56 U/L (standard reference range; varies by laboratory) Expected to change Within-group fall in the main trial (Kohno 2018); pair with AST (aspartate aminotransferase, a second liver enzyme)
TSH About 0.4–4.0 mIU/L (standard reference range) Safety check for antithyroid effect of vitexin Morning draw; add free T4 (thyroxine, the main thyroid hormone) if abnormal
Ferritin About 24–336 ng/mL in men and 11–307 ng/mL in women (standard reference range) Safety check for reduced iron absorption Inflammation raises ferritin; pair with transferrin saturation
Tacrolimus or cyclosporine trough No established target for this purpose; track against the transplant team’s individual target Safety check (reductions were reported) Drawn just before the morning dose (Hu 2024; Li 2014)
Mung bean or Vig r 1 specific IgE No established target; a positive result indicates sensitization Safety check for allergy before first use Relevant for birch-pollen, soy, peanut, or lupin allergy (Mittag 2005)

Qualitative markers:

  • Digestive tolerance: bloating, cramping, or stool changes during the first two weeks
  • Oral itching or lip swelling after doses, an early sign of pollen-related allergy
  • Shakiness, sweating, or hunger between meals, signs of low blood sugar in people on glucose-lowering drugs
  • Strength progression in training logs for protein forms
  • Fatigue, cold intolerance, or weight gain, possible signs of reduced thyroid function

Emerging Research

  • No ongoing registered trials: ClinicalTrials.gov lists no recruiting or active trial of a mung bean extract or mung bean protein for health outcomes as of November 2026, so no pending result is positioned to change this review’s conclusion soon.
  • GLUCODIA placebo-controlled trial (NCT02322294): An 8-week trial in 50 Canadian adults run by KGK Science, registered as completed (primary completion March 2016) with no results posted; its design matches the manufacturer’s main study (Kohno 2018). Posted results would allow independent checking of the between-group outcomes.
  • Triticale and mung bean in type 2 diabetes (NCT02999867): A 180-patient, 30-day whole-food trial at Peking Union Medical College Hospital, completed July 2017 with no results posted and no publication found; it tests whole beans, not an extract.
  • Vegetarian protein trial (NCT04076982): Completed January 2019 and published as Bartholomae 2019; its borderline strength result is reported under Expected Benefits.
  • Human inflammation trials: Mouse sepsis survival and HMGB1 data (Zhu 2012) have not been tested in people; a controlled human trial measuring inflammatory markers could raise or close the inflammation item.
  • Bioavailability work: Vitexin’s heavy first-pass loss (Xue 2014) drives encapsulation research using mung bean protein nanoparticles (Rodklongtan 2025); better absorption could strengthen effects or raise thyroid exposure.
  • Thyroid safety: Rat antithyroid data (Gaitan 1995) have no human counterpart for concentrated seed-coat extracts; human thyroid-function data could weaken the case if suppression appears.
  • Mammalian aging and brain models: Roundworm lifespan (Tao 2021) and worm neurodegeneration findings (Chen 2026) await rodent lifespan and cognition studies, which could either support or undercut the longevity framing.
  • Allergenicity of isolates: Processing studies show protein isolates retain cupin allergens (Chin 2024); allergy surveillance as mung bean protein foods spread may widen the population at risk.

Conclusion

Mung bean extract covers two products: concentrates of the bean’s outer coat, rich in plant pigments, and protein powders or fragments drawn from the bean. The evidence for each differs sharply.

For the protein forms, a few small, short human studies point to possible improvements in insulin levels, blood vessel function, and strength, but each comparison against the control group was weak, borderline, or relied on markers that are not established treatment targets. The main metabolic studies were run by the company that sells the leading branded protein, and the best-known magazine article promoting the extract comes from a supplement retailer; both are conflicts of interest. For the coat extracts, which carry the longevity framing, one small human study addressed cancer radiation tolerance; otherwise support comes from mice, roundworms, and cell cultures: longer worm lifespan, better survival in mice with severe blood infection, and less toxic protein clumping in worm models of brain disease. Whether this occurs in healthy people is unknown, and the main coat pigments are poorly absorbed.

Risks appear modest at food-like amounts but are not systematically measured. Allergic reactions occur in some people with birch-pollen allergy and may in those allergic to soy or peanut; reports link mung bean products to lower levels of transplant anti-rejection drugs; animal work raises thyroid questions, and reduced iron absorption is theoretical.

For health-focused adults, the picture is of an inexpensive, food-derived product whose benefits remain largely unproven in humans and whose longevity claims rest on laboratory models.

Top - Benefits - Risks - Protocol